Search for content, post, videos

BioInvent streamlines agreement on its BI-1206 antibody

BioInvent International has restructured a clinical development agreement with Cancer Research UK (CRUK) for its anti-FcγRIIB antibody, BI-1206. In exchange for a one-time payment, the revised deal simplifies and reduces BioInvent’s obligations to CRUK, which provides BioInvent with more flexi
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.